Corbus appoints Anne Altmeyer, Ph.D. to Board of Directors

Corbus Pharmaceuticals Holdings, Inc.

Dr. Altmeyer appointed to the Board effective September 20, 2022, until next annual meeting.
She receives initial option to purchase 159,200 shares of common stock and $40,000 annual cash retainer.
Altmeyer is President & CEO of TigaTx, former CBO at Sigilon Therapeutics and Adicet Bio, and held roles at Novartis and Baxalta.
Appointment brings oncology R&D and corporate development expertise to Corbus pipeline expansion.
Standard indemnification agreement executed; no reportable transactions under Item 404(a).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anne Altmeyer

Director

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Effective: 2022-09-20
Filed: September 26, 2022, 7:59 PM ET

appointed Anne Altmeyer, Ph.D., MBA, MPH, age 58, to serve as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anne Altmeyer was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Anne Altmeyer, Ph.D., MBA, MPH, age 58, to serve as a member of the Board.

View on SEC.gov

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-018857

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.